Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy

School of Medicine, University of Patras, Rhion, West Greece, Greece
Neurology (Impact Factor: 8.3). 01/2007; 67(12):2253-5. DOI: 10.1212/01.wnl.0000249344.99671.d4
Source: PubMed

ABSTRACT We conducted a randomized, open-label, controlled trial to assess the efficacy of oxcarbazepine for prophylaxis against oxaliplatin-induced peripheral neuropathy (OxIN). Thirty-two patients with colon cancer received 12 courses of the FOLFOX-4 regimen and were randomly assigned to receive oxcarbazepine (600 mg BID) or chemotherapy without oxcarbazepine. The incidence of OxIN was strikingly decreased in patients receiving oxcarbazepine (31.2% vs 75%). Oxcarbazepine may prevent OxIN symptoms. Further larger placebo-controlled trials are warranted to confirm our results.

  • Source
    • "However, this Phase II trial was designed to accrue 51 patients to each treatment group but only 19 patients received carbamazepine and 17 did not; therefore, this trial was significantly underpowered. Argyriou et al (2006c) evaluated oxcarbazepine in patients treated with oxaliplatin in a pilot, randomized, but not placebo-controlled trial. Oxcarbazepine affects both sodium and calcium channels and therefore may be more effective. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chemotherapy-induced peripheral neuropathy (CIPN) is still a common and disabling side effect of many chemotherapy agents in use today. Unfortunately, neither prophylactic strategies nor symptomatic treatments have proven useful yet. This review will discuss the diagnosis and evaluation of neuropathy in cancer patients, as well as reviewing the various prophylactic and symptomatic treatments that have been proposed or tried. However, sufficient evidence is lacking to recommend any of these treatments to patients suffering with CIPN. Therefore, the best approach is to treat symptomatically, and to start with broad-spectrum analgesic medications such as non-steroidal anti-inflammatory drugs (NSAIDs). If NSAIDs fail, a reasonable second-line agent in properly selected patients may be an opioid. Unfortunately, even when effective in other types of neuropathic pain, anti-depressants and anticonvulsants have not yet proven effective for treating the symptoms of CIPN.
    British Journal of Haematology 02/2009; 145(1):3-14. DOI:10.1111/j.1365-2141.2008.07558.x · 4.96 Impact Factor
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: An untraditional mechanism of the bulk dense plasma creation in pseudospark discharge, which allows explanation of the main peculiarities concerned with its appearance, is proposed. This mechanism is based on the plasma-beam heating of the plasma electrons through the plasma waves, which are excited by electron beam, and ionization of the gas filling atoms by these hot electrons
    Discharges and Electrical Insulation in Vacuum, 1996. Proceedings. ISDEIV., XVIIth International Symposium on; 08/1996
Show more


Available from